ReviewMolecules (Basel, Switzerland)2023
American Ginseng for the Treatment of Alzheimer's Disease: A Review.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Ginsenosides for Multi-target Intervention in Alzheimer's Disease: Current Evidence, Challenges, and Future Directions.Molecular neurobiology · 2026Review
- Shichangpu-Xiyangshen Herb Extract Alleviates Cognitive Dysfunction in Type 1 Diabetes Through Metabolism of Arachidonic Acid Cyclooxygenase and Lipoxygenase.Molecules (Basel, Switzerland) · 2026Article
- Recent Progress in the Regioselective Biotransformation and Multitarget Therapeutic Potential of Ginsenoside Rd.Molecules (Basel, Switzerland) · 2026Review
- Ginsenoside Rg3-encapsulated pegylated niosomes exhibit multimodal therapeutic potential in Alzheimer's disease.Scientific reports · 2025Article
- Neuroprotection and Enhanced Learning and Memory Abilities of Steamed American Ginseng (Food science & nutrition · 2025Article
- Neuroprotective Properties of Clove (Biomolecules · 2025Review
- Therapeutic Mechanisms of Medicine Food Homology Plants in Alzheimer's Disease: Insights from Network Pharmacology, Machine Learning, and Molecular Docking.International journal of molecular sciences · 2025Article
- Pharmacokinetics and tissue distribution analysis of ginsenoside RhFrontiers in pharmacology · 2025Article
- Phytotherapy in Alzheimer's Disease-A Narrative Review.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a prevalent degenerative condition that is increasingly affecting populations globally. American ginseng (AG) has anti-AD bioactivity, and ginsenosides, as the main active components of AG, have shown strong anti-AD effects in both in vitro and in vivo studies. It has been reported that ginsenosides can inhibit amyloid β-protein (Aβ) production and deposition, tau phosphorylation, apoptosis and cytotoxicity, as well as possess anti-oxidant and anti-inflammatory properties, thus suppressing the progression of AD. In this review, we aim to provide a comprehensive overview of the pathogenesis of AD, the potential anti-AD effects of ginsenosides found in AG, and the underlying molecular mechanisms associated with these effects. Additionally, we will discuss the potential use of AG in the treatment of AD, and how ginsenosides in AG may exert more potent anti-AD effects in vivo may be a direction for further research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.